靶向基因表达谱预测脑膜瘤结局与放疗反应
研究基于173例脑膜瘤发现队列开发了34基因表达风险评分,并在来自3大洲12家机构的1856例独立脑膜瘤(含103例前瞻性临床试验病例)中进行临床与分析验证。该生物标志物对局部复发(5年AUC 0.81)和总生存(5年AUC 0.80)的区分度优于所有其他 tested 系统,并识别出可从术后放疗获益的脑膜瘤(HR 0.54,95%CI 0.37-0.78,P=0.0001)。
要点
- 34基因表达风险评分在1856例独立脑膜瘤中完成临床与分析验证。
- 局部复发5年AUC 0.81,总生存5年AUC 0.80,优于WHO 2021分级等9种系统。
- 生物标志物识别术后放疗获益脑膜瘤(HR 0.54,95%CI 0.37-0.78,P=0.0001)。
核心结论
- 靶向基因表达生物标志物提高了脑膜瘤结局的区分度,包括预测术后放疗反应。
研究设计与样本
- 研究基于173例脑膜瘤发现队列开发34基因表达风险评分。
- 在来自3大洲12家机构的1856例独立脑膜瘤中进行临床与分析验证,包括103例来自前瞻性临床试验的脑膜瘤。
主要发现
- 基因表达生物标志物对局部复发的5年AUC为0.81,对总生存的5年AUC为0.80。
- 临床验证队列中,基因表达生物标志物对结局的区分度优于所有其他 tested 系统(N=9)。
- 与标准治疗WHO 2021分级相比,局部复发AUC增加0.11(95%CI 0.07-0.17,P<0.001)。
- 基因表达生物标志物识别出可从术后放疗获益的脑膜瘤(HR 0.54,95%CI 0.37-0.78,P=0.0001)。
- 基因表达生物标志物提示29.8%患者的术后管理可被优化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgery is the mainstay of treatment for meningioma, the most common primary intracranial tumor, but improvements in meningioma risk stratification are needed and indications for postoperative radiotherapy are controversial. Here we develop a targeted gene expression biomarker that predicts meningioma outcomes and radiotherapy responses. Using a discovery cohort of 173 meningiomas, we developed a 34-gene expression risk score and performed clinical and analytical validation of this biomarker on independent meningiomas from 12 institutions across 3 continents (N = 1,856), including 103 meningiomas from a prospective clinical trial. The gene expression biomarker improved discrimination of outcomes compared with all other systems tested (N = 9) in the clinical validation cohort for local recurrence (5-year area under the curve (AUC) 0.81) and overall survival (5-year AUC 0.80). The increase in AUC compared with the standard of care, World Health Organization 2021 grade, was 0.11 for local recurrence (95% confidence interval 0.07 to 0.17, P < 0.001). The gene expression biomarker identified meningiomas benefiting from postoperative radiotherapy (hazard ratio 0.54, 95% confidence interval 0.37 to 0.78, P = 0.0001) and suggested postoperative management could be refined for 29.8% of patients. In sum, our results identify a targeted gene expression biomarker that improves discrimination of meningioma outcomes, including prediction of postoperative radiotherapy responses.
引用
- Chen WC, Choudhury A, Youngblood MW, et al. Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. Nat Med. 2023. PMID: 37944590. doi:10.1038/s41591-023-02586-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。